

## CLAIMS:

1. Inclusion complexes having significantly improved oral efficacy and prolonged duration of action selected from the group consisting of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with a cyclodextrin derivative.
- INS  
A1 2. Inclusion complex as claimed in claim 1 the cyclodextrin derivative is selected from beta cyclodextrin, hydroxypropyl-beta cyclodextrin, dimethyl-beta cyclodextrin, hydroxyethyl-beta-cyclodextrin.
3. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.
4. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl beta-cyclodextrin.
5. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl beta-cyclodextrin.
6. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with dimethyl beta-cyclodextrin.
- INS  
A2 7. Inclusion complex as claimed in claim 1 wherein the molar ratio between L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and said cyclodextrin derivative is 1:5 to 2:1.
8. Pharmaceutical compositions comprising a therapeutically effective amount of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin as claimed in claim 1 having

~~INS  
A3~~ improved analgesic activity with longer duration of action as compared with the free peptide.

9. Pharmaceutical composition as claimed in claim 8 having potential for clinical application as an analgesic.
10. Pharmaceutical composition as claimed in claim 8 formulated in various physical forms such as tablets, injections, capsules.
11. A method for the treatment of acute inflammations and for alleviating pain comprising the step of administration of pharmaceutical composition containing the inclusion complex as claimed in claim 1 to a patient in need thereof.
12. A method as claimed in claim 11 wherein inclusion complex is administered orally or transdermally or rectal route.
13. A method as claimed in claim 11 wherein the pharmaceutical composition of claim 8 exhibits significant analgesic activity with reduced dependence liability, respiratory depression, gastric irritation and sedation.
14. A method as claimed in claim 11 for the treatment of acute inflammations and for alleviating pain, which comprises oral administration of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin as claimed in claim 1.
15. A method for the treatment of acute inflammations and for alleviating pain, which comprises topical application of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta cyclodextrin as claimed in claim 1.